[Retracted] Circular RNA circHIPK3 Promotes Cell Metastasis through miR‐637/STAT3 Axis in Osteosarcoma

Huang, Zhongwen; Yuan, Chunyan; Gu, Huijie; Cheng, Xiangyang; Zhou, Kaifeng; Xu, Jun; Yin, Xiaoxing; Xia, Jiangni

doi:10.1155/2020/2727060

Cited by 16 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jinjin Lai et al showed that circHIPK3 promotes the proliferation and metastasis of renal cancer cells by downregulating miR-485-3p ( 45 ). The metastasis of osteosarcoma cells is mediated through the circHIPK3-miR-637/STAT3 signaling pathway ( 46 , 47 ). In animal experiments, circHIPK3 promoted the proliferation and metastasis of esophageal squamous cell carcinoma cells by mediating the circHIPK3-miR-599/c-MYC signaling pathway ( 48 ).…”

Section: Circhipk3 Biogenesismentioning

confidence: 99%

CircHIPK3: Key Player in Pathophysiology and Potential Diagnostic and Therapeutic Tool

et al. 2021

View full text Add to dashboard Cite

A large number of studies in China and other countries have confirmed that circularHIPK3 (circHIPK3) plays an important role in the pathophysiological processes of various diseases. Through the action of sponge miRNA (miR), circHIPK3 regulates cell proliferation, differentiation, and migration, and plays a key role in disease processes. By referring to a large number of research reports, this article explores the specific functional role of circHIPK3 in fibrotic diseases, cancer, and other diseases. This review aims to clarify the role of circHIPK3 in disease processes in order to aid further studies into the specific pathogenesis and clinical diagnosis of various diseases and provide new ideas for treatments.

show abstract

Section: Circhipk3 Biogenesismentioning

confidence: 99%

CircHIPK3: Key Player in Pathophysiology and Potential Diagnostic and Therapeutic Tool

et al. 2021

View full text Add to dashboard Cite

show abstract

“…11,12 We previously confirmed that microRNA-637 (miR-637) is a favorable prognosis marker in glioma that targets the 3ʹ-untranslated region (UTR) of Akt1. 13 Further targets of miR-637, such as signal transducer and activator of transcription 3 (STAT3) and SOX10, 14,15 have been validated so far, but there remains a lack of knowledge regarding upstream regulation.…”

Section: Introductionmentioning

confidence: 99%

Oncogenic ZEB2/miR-637/HMGA1 signaling axis targeting vimentin promotes the malignant phenotype of glioma

Zeng

Que

Lin

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Glioma is the most common primary tumor of the central nervous system. We previously confirmed that zinc finger E-box binding homeobox (ZEB) 2 promotes the malignant progression of glioma, while microRNA-637 (miR-637) is associated with favorable prognosis in glioma. This study aimed to investigate the potential interaction between ZEB2 and miR-637 and its downstream signaling pathway in glioma. The results revealed that ZEB2 could directly bind to the E-box elements in the miR-637 promoter and promote cell proliferation, migration, and invasion via miR-637 downregulation. Subsequent screening confirmed that HMGA1 was a direct target of miR-637, while miR-637 could drive the malignant phenotype of glioma by suppressing HMGA1 both in vitro and in vivo. Furthermore, interaction between cytoplasmic HMGA1 and vimentin was observed, and vimentin inhibition could abolish increased migration and invasion induced by HMGA1 overexpression. Both HMGA1 and vimentin were associated with an unfavorable prognosis in glioma. Additionally, upregulated HMGA1 and vimentin were found in isocitrate dehydrogenase (IDH) wild-type and 1p/19q non-codeletion diffusely infiltrating glioma. In conclusion, we identified an oncogenic ZEB2/miR-637/HMGA1 signaling axis targeting vimentin that promotes both migration and invasion in glioma.

show abstract

“…Among them, the expression level of miR-637 in various cancer tissues was significantly lower than that in adjacent tissues, including glioblastoma and lowgrade gliomas (GBM/LGG) [8][9][10][11], papillary thyroid carcinoma (PTC) [12,13], non-small cell lung cancer (NSCLC) [14], gastric cancer (GC) [15][16][17], hepatocellular carcinoma (HCC) [18][19][20][21], CRC [22], pancreatic ductal adenocarcinoma (PDAC) [23], human cholangiocarcinoma (CHOL) [24], oral squamous cell carcinoma (OSCC) [25], prostate cancer (PCa) [26], ovarian cancer (OC) [27,28], triple-negative breast cancer (TNBC) [29], cervical cancer (CCa) [30], osteosarcoma (SaOS) [31,32], multiple myeloma (MM) [33], chronic myeloid leukemia (CML) [34]. In addition, the expression level of miR-637 was lower in the cell lines of various cancer cells than the corresponding normal cell lines, including PTC [12,13], GC [17], HCC [18,21], OSCC [35], PDAC [23], CHOL [36], TNBC [37], breast cancer (BRCA) [38], SaOS [31], etc. In the serum of CHOL patients, the expression level of miR-637 was lower than that of healthy people [39].…”

Section: Mir-637 Is Abnormally Expressed In Human Cancersmentioning

confidence: 99%

Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis

Shen

Liang

et al. 2022

Biomark Res

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of small non-coding RNAs ranging from 17 to 25 nt in length. miR-637 is down-regulated in most cancers and up-regulated only in clear cell renal cell carcinoma (ccRCC). miR-637 can target 21 protein-coding genes, which are involved in the regulation of cell growth, cell cycle, cell proliferation, epithelial-mesenchymal transition (EMT), cancer cell invasion and metastasis, etc. In glioma, the transcription factor ZEB2 can bind to the miR-637 promoter region and inhibit miR-637 expression. Besides, miR-637 could be negatively regulated by competing endogenous RNA (ceRNAs) comprising 13 circular RNA (circRNAs) and 9 long non-coding RNA (lncRNAs). miR-637 is involved in regulating five signaling pathways, including the Jak/STAT3, Wnt/β-catenin, PI3K/AKT, and ERK signaling pathways. Low miR-637 expression was significantly associated with larger tumors and later tumor node metastasis (TNM) staging in cancer patients. Low miR-637 expression was also associated with poorer overall survival (OS) in cancer patients such as glioblastoma and low-grade gliomas (GBM/LGG), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and ovarian cancer (OV). Low expression of miR-637 increases the resistance of colorectal cancer (CRC) and human cholangiocarcinoma (CHOL) cancer cells to three anticancer chemotherapeutics (gemcitabine (dFdC), cisplatin (DDP), and oxaliplatin (OXA)). Our work summarizes the abnormal expression of miR-637 in various cancers, expounds on the ceRNA regulatory network and signaling pathway involved in miR-637, and summarizes the effect of its abnormal expression on the biological behavior of tumor cells. At the same time, the relationship between the expression levels of miR-637 and its related molecules and the prognosis and pathological characteristics of patients was further summarized. Finally, our work points out the insufficiency of miR-637 in current studies and is expected to provide potential clues for future miR-637-related studies.

show abstract

[Retracted] Circular RNA circHIPK3 Promotes Cell Metastasis through miR‐637/STAT3 Axis in Osteosarcoma

Cited by 16 publications

References 35 publications

CircHIPK3: Key Player in Pathophysiology and Potential Diagnostic and Therapeutic Tool

CircHIPK3: Key Player in Pathophysiology and Potential Diagnostic and Therapeutic Tool

Oncogenic ZEB2/miR-637/HMGA1 signaling axis targeting vimentin promotes the malignant phenotype of glioma

Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis

Contact Info

Product

Resources

About